| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A104 | Bemarituzumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody) Featured | Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. |
.png)
|
| A105 | Vofatamab Biosimilar(Anti-FGFR3 / CD333 Reference Antibody ) Featured | Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
.png)
|
| A106 | U3-1784 Biosimilar(Anti-FGFR4 / CD334 Reference Antibody) Featured |
|
|
| A107 | Radretumab Biosimilar(Anti-Fibronectin Reference Antibody) Featured |
.png)
|
|
| DC66691 | L19TNF Featured |
|
|
| A109 | Rosopatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody) Featured | Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency. |
.png)
|
| A110 | Pelgifatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody) Featured | Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research. |
.png)
|
| A111 | Mirvetuximab Biosimilar(Anti-FOLR1 / FRA Reference Antibody) Featured | Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research. |
.png)
|
| DC66695 | Cofrogliptin Featured | Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) . |
|
| DC66696 | (R)-2-Thioxothiazolidine-4-carboxylic acid-13C3 Featured | (R)-2-Thioxothiazolidine-4-carboxylic acid-13C3 is the 13C-labeled (R)-2-Thioxothiazolidine-4-carboxylic acid. Radioactive isotopes labeled compounds can be used in metabolic analysis, allowing the movement of individual atoms to be precisely tracked and quantified. |
|
| DC66697 | 2-Thioxothiazolidine-4-carboxylic Acid Featured |
|
|
| DC66698 | STING agonist-12 Featured | STING agonist-12 (Compound 53) is a potent, orally active human STING activator with an EC50 of 185 nM. |
|
| A619 | Sacituzumab govitecan Featured | Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity. |
|
| DC66700 | (S,R)-LSN3318839 Featured | (S,R)-LSN3318839 is the stereoisomer of LSN3318839 (HY-142162). LSN3318839 is an orally active positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). |
|
| DC66701 | (3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol Featured |
|
|
| A112 | Farletuzumab Biosimilar(Anti-FOLR1 / FRA Reference Antibody) Featured | Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. |
.png)
|
| A114 | Dompe patent anti-FOLR1 Biosimilar(Anti-FOLR1 / FRA Reference Antibody) Featured |
|
|
| A116 | BMS-986012 Biosimilar（Anti-Fucosyl GM1 Reference Antibody） Featured |
|
|
| A130 | Vantictumab Biosimilar（Anti-FZD Reference Antibody） Featured | Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma. |
.png)
|
| A131 | U.Toronto patent anti-FZD7 Biosimilar（Anti-FZD7 Reference Antibody） Featured |
|
|
| DC60641 | CD-005 Featured | CD-005 is a low-molecular-weight gelator that can be used to prepare gels for proteins and vaccines. CD-005 can physically entrap proteins, preventing their irreversible aggregation, and maintain protein function for at least 4 weeks even at temperatures up to 50°C. |
|
| DC66707 | Casdatifan Featured | Casdatifanum is a hypoxia-inducible factor (HIF) inhibitor. |
|
| DC66708 | BMS-986408 Featured | BMS-986408 is a DGK inhibitor. |
|
| DC66709 | BAY-2925976 Featured | BAY-2925976 is an ARα2C antagonist. |
|
| DC66710 | AZD4144 Featured | AZD4144 is an NLRP3 inhibitor. |
|
| DC66711 | CHF-6523 Featured | CHF-6523 is an inhaled PI3Kδ inhibitor. |
|
| DC66712 | BAY-2413555 Featured |
|
|
| DC66713 | NVP-EVS459 Featured |
|
|
| DC60642 | Compound 33 (HYOU1 inhibitor) Featured | Compound 33 (HYOU1 inhibitor) is a first-in-class inhibitor of hypoxia up-regulated protein 1 (HYOU1) with EC50 of 3.2 μM/2.6 μM/16.1 μM/3.0 μM in WT-MIP3/WT-RANTES/hTNFtg-MIP3/hTNFtg-RANTES, respectively. |
.png)
|
| DC60643 | BRD-810 Featured | BRD-810 is a potent and selective MCL1 inhibitor with Kd of 0.3 nM (SPR) and IC50 of 0.4 nM (MCL1-Noxa HTRF), respectively. BRD-810 is a rapidly cleared inhibitor of MCL1 that has robust antitumor efficacy in hematological and solid tumor cancer models. |
|
